Apogee Therapeutics, Inc.
APGEDelisted Sep 3, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001974640
Apogee Therapeutics, Inc. was delisted on Sep 3, 2026; its insiders filed their last Form 4 on Sep 3, 2026; 289 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 289
- Q2 2026, +69 vs. previous quarter
- 13F value
- $8.93B
- Reported value at the end of Q2 2026
- Superinvestors holding
- 1
- At the end of Q2 2026
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$255.8M
- No comparable prior period
- Free cash flow, FY2025
- -$232.6M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Aug 31, 2026.
- Short interest
- 4.20M
- Shares sold short
- Change
- −70.4K
- −1.7% vs. previous
- Days to cover
- 3.47
- At average daily volume
Superinvestors holding APGE, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Apogee Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
1.0%
Apogee Therapeutics, Inc.'s share of the portfolio
- Shares
- 564,500
- Value
- $74.9M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Apogee Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 (view filing)8:00 PM ET | Aug 5 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $134.17 | −$737.9K | −3.2%168.5K after | 10b5-1 |
| Jul 10, 2026 (view filing)8:00 PM ET | Jul 8 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $133.63 | −$2.67M | −2.0%996.0K after | 10b5-1 |
| Jul 2, 2026 (view filing)8:13 PM ET | Jul 1 | 1 day | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $132.74 | −$730.1K | −3.0%177.9K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −26.4K | $132.60 | −$3.50M | −12.8%179.2K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −80.0K | $132.54 | −$10.6M | −7.3%1.02M after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 10 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $83.38 | −$1.67M | −1.8%1.10M after | 6 lots10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $78.71 | −$432.9K | −2.6%205.6K after | 10b5-1 |
| May 15, 2026 (view filing) | May 13 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $82.09 | −$1.64M | −1.8%1.12M after | 2 lots10b5-1 |
| May 8, 2026 (view filing) | May 6 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $84.14 | −$462.8K | −2.6%207.0K after | 2 lots10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Henderson JaneChief Financial Officer | SSale | −2.00K | $82.04 | −$164.1K | −1.1%173.4K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 289 holdersThe largest institutional positions in Apogee Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VR Adviser, LLC | 8,493,321 | $1.13B | 34.18% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,507,032 | $730.9M | 0.01% | +1,421,381+34.8% | Added |
| HBK Investments L P | 2,850,000 | $378.3M | 4.40% | +2,850,000 | New |
| Vanguard Capital Management LLC | 2,572,119 | $341.4M | 0.01% | +70,024+2.8% | Added |
| FMR LLC | 2,493,137 | $330.9M | 0.01% | −6,769,154−73.1% | Reduced |
| State Street Corp | 2,297,743 | $305.0M | 0.01% | +134,779+6.2% | Added |
| Driehaus Capital Management LLC | 1,740,101 | $231.0M | 1.34% | −180,699−9.4% | Reduced |
| Goldman Sachs Group Inc | 1,693,341 | $224.8M | 0.02% | +1,040,751+159.5% | Added |
| Balyasny Asset Management LLC | 1,665,102 | $221.0M | 0.40% | +1,226,448+279.6% | Added |
| Glazer Capital, LLC | 1,641,042 | $217.8M | 5.37% | +1,641,042 | New |
Holders of 5% or more of APGE
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Apogee Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 5.50%2.52M shares | – | Oct 22, 20243 filings | Jul 16, 2025 | SEC |